Clinical Trials Logo

Clinical Trial Summary

This is a multi-center, randomized, double-blind , placebo parallel controlled, standard therapy based phase III clinical trial, to evaluate the efficacy of recombinant human neuregulin-1 on cardiac remodeling, as well as safety in patients with chronic heart failure.


Clinical Trial Description

RhNRG-1(recombinant human neuregulin-1)directly works on the cardiomyocytes and restored the normal structure and function of it.Both the preclinical trial and phase II clinical trail have confirmed that rhNRG-1 effectively improved the heart function, and is tolerated in the effective dosage groups. The aim of this phase III trial is to further confirm in large population that rhRNG-1 administration can effectively improve the cardiac remodeling and is tolerated in patients with chronic heart failure. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01439893
Study type Interventional
Source Zensun Sci. & Tech. Co., Ltd.
Contact
Status Terminated
Phase Phase 3
Start date June 2011
Completion date June 2012

See also
  Status Clinical Trial Phase
Suspended NCT04589065 - SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device) N/A
Completed NCT02248441 - Effect of Remote Ischemic Conditioning in Patients With Chronic Ischemic Heart Failure N/A
Recruiting NCT02188082 - Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets (FIRST) Phase 2/Phase 3
Recruiting NCT03504891 - Cardiac MRI for Optimal Heart Failure Outcomes With CRT Upgrades Phase 1
Active, not recruiting NCT04468529 - Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure Phase 3
Active, not recruiting NCT01639378 - Renal Artery Denervation in Chronic Heart Failure Study Phase 3
Recruiting NCT05949801 - Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure Phase 3
Completed NCT02809131 - Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. Phase 3